Immunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS Trial [Yahoo! Finance]
Immunic, Inc. (IMUX)
Company Research
Source: Yahoo! Finance
The trial evaluated vidofludimus calcium (IMU-838), which is an orally available nuclear receptor-related 1 (Nurr1) activator, in patients with relapsing-remitting multiple sclerosis/RRMS. The cumulative data from the EMPhASIS OLE period, which shows ~952 treatment years, further support the favorable safety and tolerability profile of vidofludimus calcium, showing low discontinuation rates and minimal treatment-emergent and serious adverse events. Importantly, no new safety signals have emerged during treatment durations extending up to 5.5 years. The Phase 2 EMPhASIS trial was an international, multicenter, double-blind, placebo-controlled, randomized, parallel-group study that initially randomized 268 RRMS patients. A closeup of pills in a pharmacy, representing the high quality medications of the company. Vidofludimus calcium (IMU-838) is an orally administered investigational small molecule drug in late-stage clinical trials for multiple sclerosis. Its unique dual mode of a
Show less
Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMUX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMUX alerts
High impacting Immunic, Inc. news events
Weekly update
A roundup of the hottest topics
IMUX
News
- Immunic (NASDAQ:IMUX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Immunic (NASDAQ:IMUX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December [Yahoo! Finance]Yahoo! Finance
- Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in DecemberPR Newswire
- Immunic (NASDAQ:IMUX) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.MarketBeat
IMUX
Earnings
- 11/13/25 - Beat
IMUX
Sec Filings
- 12/8/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- IMUX's page on the SEC website